Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: a systematic review

Detalhes bibliográficos
Autor(a) principal: Oliveira, Ana Gabriela
Data de Publicação: 2020
Outros Autores: Gonçalves, Margarida, Ferreira, Helena, Neves, N. M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/1822/66354
Resumo: Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.msard.2019.101860.
id RCAP_70e1d73bd71889a9d2dab4569f324547
oai_identifier_str oai:repositorium.sdum.uminho.pt:1822/66354
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: a systematic reviewAdverse eventsExpanded disability status scaleMesenchymal stem cellsMultiple sclerosisTherapeutic efficacyScience & TechnologySupplementary material associated with this article can be found, in the online version, at doi:10.1016/j.msard.2019.101860.Background: Multiple sclerosis (MS) typically arises in early/middle adulthood and is characterized by a progressive disability of the central nervous system (CNS). Currently approved therapies do not promote tissue repair or stop disease progression. Emerging data demonstrate that stem cells present a great potential in regenerative medicine and, consequently, have also been widely investigated as a potential treatment for MS. Therefore, the aim of this study was to conduct a systematic review to inquire into the safety, tolerability, and efficacy of mesenchymal stem cells (MSCs) therapies in MS. Methods: Three electronic databases (Web of Science, PubMed, and Cochrane) were searched from April until June 2019. Clinical trials or case reports with information related to the effects of MSC therapies in MS patients were considered for this review. Results: 10 manuscripts were selected, namely 7 uncontrolled clinical trials, 2 randomized controlled clinical trials, and 1 case report. The overall quality of the studies was considered good. Besides minor adverse events (AEs), it was reported one case of encephalopathy with seizures and two cases of iatrogenic meningitis, which were not related to the treatment, but with the administration route. The analyses of the expanded disability status scale (EDSS) in the uncontrolled clinical trials demonstrated that 48 patients improved, 39 maintained and 16 worsened their clinical condition. Regarding the randomized studies, one did not show statistically significant variations in the mean EDSS score and in the other the mean EDSS score was statistically significantly lower for the experimental group. The case report also showed an improvement in the EDSS score. Conclusions: MSCs transplantation proved to be a safe and tolerable therapy. Their potential therapeutic benefits were also validated. However, larger placebo controlled blinded clinical trials will be required to establish the long term safety and efficacy profile of these therapies for MS. Their translation into the clinical practice can provide a new hope for the patients of this highly debilitating disease.ElsevierUniversidade do MinhoOliveira, Ana GabrielaGonçalves, MargaridaFerreira, HelenaNeves, N. M.2020-022020-02-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/1822/66354engOliveira A. G., Gonçalves M., Ferreira H., Neves N. M. Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: A systematic review, Multiple Sclerosis and Related Disorders, Vol. 38, pp. 101860, doi:10.1016/j.msard.2019.101860, 20202211-034810.1016/j.msard.2019.10186031765999https://www.sciencedirect.com/science/article/pii/S2211034819308491?via%3Dihub#!info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:29:00Zoai:repositorium.sdum.uminho.pt:1822/66354Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:23:55.035951Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: a systematic review
title Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: a systematic review
spellingShingle Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: a systematic review
Oliveira, Ana Gabriela
Adverse events
Expanded disability status scale
Mesenchymal stem cells
Multiple sclerosis
Therapeutic efficacy
Science & Technology
title_short Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: a systematic review
title_full Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: a systematic review
title_fullStr Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: a systematic review
title_full_unstemmed Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: a systematic review
title_sort Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: a systematic review
author Oliveira, Ana Gabriela
author_facet Oliveira, Ana Gabriela
Gonçalves, Margarida
Ferreira, Helena
Neves, N. M.
author_role author
author2 Gonçalves, Margarida
Ferreira, Helena
Neves, N. M.
author2_role author
author
author
dc.contributor.none.fl_str_mv Universidade do Minho
dc.contributor.author.fl_str_mv Oliveira, Ana Gabriela
Gonçalves, Margarida
Ferreira, Helena
Neves, N. M.
dc.subject.por.fl_str_mv Adverse events
Expanded disability status scale
Mesenchymal stem cells
Multiple sclerosis
Therapeutic efficacy
Science & Technology
topic Adverse events
Expanded disability status scale
Mesenchymal stem cells
Multiple sclerosis
Therapeutic efficacy
Science & Technology
description Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.msard.2019.101860.
publishDate 2020
dc.date.none.fl_str_mv 2020-02
2020-02-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/1822/66354
url https://hdl.handle.net/1822/66354
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Oliveira A. G., Gonçalves M., Ferreira H., Neves N. M. Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: A systematic review, Multiple Sclerosis and Related Disorders, Vol. 38, pp. 101860, doi:10.1016/j.msard.2019.101860, 2020
2211-0348
10.1016/j.msard.2019.101860
31765999
https://www.sciencedirect.com/science/article/pii/S2211034819308491?via%3Dihub#!
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799132716148457472

Registros relacionados